Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Expectations for June Phase 2 PEARL Trial

Canaccord Genuity reiterates a 'Buy' on Anthera Pharma (NASDAQ: ANTH) price target of $6.00.

Analyst, Ritu Baral, said, "Reiterate rating and price target on blisibimod (B--mod) clinical and commercial potential in lupus. We expect B-mod, ANTH’s BAFF peptibody for lupus, will yield positive data from the Phase 2 PEARL trial in June and ANTH to start the Phase 3 Chablis trial in Q1/13. ANTH may start Phase 2 B-mod trials in other lupus-related B cell disorders to leverage market potential and diversify clinical risk."

For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.

Shares of Anthera Pharma closed at $2.32 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris